Opinion
Video
Author(s):
The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
U.S. News & World Report Names Michigan Institute of Urology’s Town Center ASC Among 2025 Best Ambulatory Surgery Centers
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
Exploring new avenues in non–muscle invasive bladder cancer treatment
FDA approval sought for Anktiva in papillary NMIBC